AUR104

Phase 1Small molecule

AAurigene Discovery Technologies Limited

AUR104 is one of 6 small molecule programs targeting Lymphoid Malignancies. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lymphoid MalignanciesRecruiting

Lymphoid MalignanciesPhase 1

Recruiting

Competition

Competitive Landscape

6 competitors in Lymphoid Malignancies

#DrugCompanyPhaseTrials

Fludara

Sanofi

Phase 2

6 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

7 3

Tazverik

EEpizyme, Inc.

Phase 1

1 4

Folotyn

AAcrotech Biopharma Inc.

Preclinical

1 5

AVM0703

AAVM Biotechnology Inc

Phase 2

1 6

AUR104

AAurigene Discovery Technologies Limited

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Lymphoid Malignancies

NCT06761586

Clinical

Trials by Indication[1]

Lymphoid Malignancies1 trial

A Study of AUR104 in Patients With Relapsed/Refractory Lymphoid Malignancies (VIJAY-1)

Recruiting·AAurigene Discovery Technologies Limited·Phase 1·NCT06761586·42 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AUR104. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AUR104 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AUR104. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Aurigene Discovery Technologies Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAurigene Discovery Technologies Limited

AUR104

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Lymphoid Malignancies1 trial

References

Drug Info

Quick Facts

Related News